<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628689</url>
  </required_header>
  <id_info>
    <org_study_id>FMBSUREC/01092020/Abd El Badei</org_study_id>
    <nct_id>NCT04628689</nct_id>
  </id_info>
  <brief_title>Quadratus Lumborum Block by Paraspinous Sagittal Shift Approach With Different Concentrations Of Bupivacaine in Hip Surgeries</brief_title>
  <official_title>Comparison Of The Analgesic Efficacy Of Quadratus Lumborum Block By Paraspinous Sagittal Shift Approach With Different Concentrations Of Bupivacaine in Hip Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the optimum concentration of bupivacaine in Paraspinous&#xD;
      Sagittal Shift Approach for Quadratus Lumborum Block in hip Surgeries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the patient in the lateral decubitus and the block side independent, a curvilinear&#xD;
      ultrasound transducer (2-5 MHz) will be directed caudally in a sagittal plane 3-4 cm lateral&#xD;
      to the lumbar spinous process of L4, which is almost opposite to the iliac crest, producing a&#xD;
      longitudinal scan of the lumbar paravertebral region; and thus identifying the transverse&#xD;
      processes of L3 and L4, with PM muscle in-between and erector spinae muscle posteriorly.&#xD;
&#xD;
      The probe is shifted slowly to the lateral side until the transverse processes disappear and&#xD;
      the QL muscle is evident in its long axis attached caudally to the iliac crest with a&#xD;
      characteristic sonographic image of three muscle layers appearing from posterior to anterior&#xD;
      as: erector spinae, QL, and PM muscles respectively. After subcutaneous local infiltration&#xD;
      with lidocaine at the cephalic end of the probe, the block needle is advanced in a&#xD;
      cephalo-caudal direction, through the erector spinae and QL muscles, until it pierces the&#xD;
      epimysium of the QL. LA is injected anterior to the QL muscle, observing its spread in a&#xD;
      caudal direction towards the iliac crest between the QL and psoas muscles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to first request of analgesics</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <description>Postoperative time to first request of analgesics (hours)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Hip Surgeries</condition>
  <arm_group>
    <arm_group_label>Group 0.25% bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 ml 0.25% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 0.375% bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.375% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quadratus lumborum block by paraspinous sagittal shift approach</intervention_name>
    <description>quadratus lumborum block by paraspinous sagittal shift approach</description>
    <arm_group_label>Group 0.25% bupivacaine</arm_group_label>
    <arm_group_label>Group 0.375% bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I and II undergoing hip surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for regional blocks (eg. Patient refusal Infection at the injection&#xD;
             site, coagulopathy) allergic reaction to drugs. opium addiction, any drug or substance&#xD;
             abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>doaa rashwan</last_name>
    <phone>00201011270763</phone>
    <email>doaa_rashwan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Benisuef univercity</name>
      <address>
        <city>BanÄ« Suwayf</city>
        <state>Benisuef</state>
        <zip>62511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doaa Rashwan, MD</last_name>
      <phone>01011270763</phone>
      <email>doaa_rashwan@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Samaa Rashwan, MD Rashwan, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>doaa rashwan</investigator_full_name>
    <investigator_title>Assistant professor Doaa Rashwan</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

